Financial Data and Key Metrics Changes - Total operating income for 2019 reached €82.6 million, an increase of €53.4 million compared to 2018, attributed to collaboration with Janssen and milestone payments from AbbVie [31] - Total expenses for 2019 were €197.7 million, up from €83.6 million in 2018, driven by increased R&D and SG&A expenditures [32] - The net loss for 2019 was €163 million, compared to €66.6 million in 2018, with cash equivalents increasing to €1.3 billion from €565 million in 2018 [33] Business Line Data and Key Metrics Changes - The company is advancing its pipeline with multiple trials ongoing for efgartigimod in various indications, including myasthenia gravis (MG), immune thrombocytopenia (ITP), pemphigus vulgaris (PV), and chronic inflammatory demyelinating polyneuropathy (CIDP) [6][12] - The Phase III ADAPT trial for MG is fully enrolled, with top-line data expected mid-year [20][21] Market Data and Key Metrics Changes - The company has received fast-track designation from the FDA for efgartigimod in MG, indicating potential for expedited review and market entry [6][7] - The company is preparing for a commercial launch in 2021, with a focus on building a global commercial team [28][30] Company Strategy and Development Direction - The company aims to become a fully integrated immunology company by 2021, focusing on innovation across its pipeline and commercial strategies [6][8] - The strategy includes a patient-tailored dosing regimen for efgartigimod, differentiating it from competitors who may use fixed dosing [26][78] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of efgartigimod, highlighting its unique mechanism of action and the importance of addressing the underlying causes of diseases like MG [26][72] - The company is optimistic about its pipeline and expects to run up to five Phase III trials and seven earlier-stage clinical trials in 2020 [34] Other Important Information - The company has initiated a real-world evidence initiative called "my real-world MG" to better understand patient perspectives and the burden of MG [27][86] - The company plans to engage with the FDA regarding the subcutaneous formulation of efgartigimod, aiming for a streamlined approval process [76] Q&A Session Summary Question: Thoughts on competitor's decision to halt an antibody program - Management noted that not all FcRn programs are equal, emphasizing the differentiation in efficacy, safety, and convenience of their product [38][39] Question: Details on mid-year data release - Management stated that mid-year is the best guidance they can provide at this time [40] Question: Patient stratification in Phase III ADAPT trial - The trial has been stratified based on geographic location, receptor positivity, and background therapies to ensure balanced results [42][43] Question: Steroid doses normalization in the trial - Steroid doses are comparable to those seen in Phase II trials, with top-line data to be released first, followed by more detailed information [44] Question: Treatment burden and subcutaneous options - Management clarified that the treatment can be administered via home infusion, and they are exploring options for subcutaneous administration to enhance patient convenience [47][48] Question: Criteria for redosing in Phase III - Patients need to lose their clinically meaningful response, defined as a two-point change from baseline, to qualify for redosing [56] Question: Update on CIDP trial enrollment - No public updates on CIDP trial enrollment have been provided yet [69] Question: FDA's perspective on ADAPT trial endpoints - Management confirmed that the primary endpoint has been discussed with the FDA, and they are focused on the clinical meaningfulness of the results [72] Question: Synergy between cusatuzumab and venetoclax - Preclinical data suggests a strong synergy between cusatuzumab and venetoclax, which could enhance treatment efficacy in AML [84]

Revenue and Income - Total revenue for the year ended December 31, 2018, decreased by €14.9 million to €21.5 million, a 41% decline compared to €36.4 million in 2017[811]. - Total operating income for 2018 was €29.2 million, a 29% decrease from €41.3 million in 2017[810]. - The company reported a total comprehensive loss of €66.6 million for 2018, a 137% increase from €28.1 million in 2017[810]. - Loss before taxes for 2018 was €65.8 million, a 140% increase from €27.5 million in 2017[810]. - The company had accumulated losses of €169.6 million as of December 31, 2018, and expects to continue incurring significant operating losses in the foreseeable future[863]. Expenses - Research and development expenses totaled €83.6 million for the year ended December 31, 2018, a 62% increase from €51.7 million in 2017, driven by higher external research and personnel expenses[818]. - Selling, general and administrative expenses increased to €27.5 million in 2018, a 121% rise from €12.4 million in 2017, mainly due to higher personnel and consulting fees[822]. - Personnel expenses in research and development increased by €10.0 million in 2018, largely due to share-based compensation and additional personnel costs[818]. - Upfront payments decreased by 57% to €8.6 million in 2018 from €20.1 million in 2017, primarily due to the completion of preclinical activities under collaborations with LEO Pharma and AbbVie[811][812]. - Research and development service fees decreased by €5.2 million, or 79%, to €1.4 million in 2018 compared to €6.6 million in 2017, linked to the completion of preclinical activities[811][815]. Research and Development - External research and development expenses rose to €48.9 million in 2018, up 75% from €27.9 million in 2017, primarily due to increased clinical trial costs[820]. - The lead product candidate efgartigimod incurred external research and development expenses of €30.9 million in 2018, a 150% increase from €12.4 million in 2017[820]. - The company employed 75 research and development personnel as of December 31, 2018, compared to 58 employees in 2017, indicating a significant increase in workforce[818]. Financial Position - Cash and cash equivalents at the end of the period increased to €281.0 million in 2018 from €190.9 million in 2017, a rise of €90.2 million[852]. - Net cash used in operating activities increased to €53.8 million in 2018, up €17.3 million from €36.5 million in 2017[852]. - The net cash inflow from financing activities was €244.7 million for the year ended December 31, 2018, compared to €305.4 million in 2017[856]. - The company expects existing cash and cash equivalents to fund operating expenses and capital expenditure requirements for at least the next 12 months[864]. Commitments and Obligations - The total commitment under the commercial supply agreement with Lonza for efgartigimod amounts to a minimum of £25.3 million over a period of five years starting from 2020[873]. - The company has outstanding commitments for efgartigimod of approximately €42.2 million and for cusatuzumab of approximately €4.5 million starting from 2019[873]. - The operating lease commitments total €3,004,000, with €1,028,000 due within one year[869]. - The purchase obligation amounts to €46,626,000, with €13,610,000 due within one year[869]. Other Financial Information - Financial income for 2018 amounted to €3.7 million, up from €1.3 million in 2017, reflecting a €2.4 million increase primarily from higher interest on cash and equivalents[826]. - Exchange gains totaled €12.3 million for the year ended December 31, 2018, attributed to favorable fluctuations in the EUR/USD exchange rate[827]. - The company has no off-balance sheet arrangements as defined by SEC regulations[867]. - The company is unable to estimate the amounts of increased operating expenses associated with completing the research and development of its product candidates due to numerous risks and uncertainties[864].